Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Environmental Research|August 11, 2025
Integrated screening techniques reveal insight into hyperlocal non-traffic emission sourcesMichelle S Hui, Jintao Gu, Timothy Baker, et al.Journal of Medical Economics|October 1, 2020
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in JapanVictoria Federico Paly, Yusuke Hikichi, Timothy Baker, et al.The Science of the Total Environment|August 17, 2014
Degradation in urban air quality from construction activity and increased traffic arising from a road widening schemeAnna Font, Timothy Baker, Ian S Mudway, et al.Journal of Health Communication|September 19, 2017
How Cancer Patients Use and Benefit from an Interactive Cancer Communication SystemJeong Yeob Han, Robert Hawkins, Timothy Baker, et al.Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention|February 20, 2025
Using emergency department data to reduce late-night alcohol-related presentations in an Australian central business districtPeter Miller, Nicholas Taylor, Diana Egerton-Warburton, et al.Pharmacoeconomics|September 19, 2002
Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature reviewMary Kay Margolis, Karin Coyne, Tessa Kennedy-Martin, et al.Substance Use & Misuse|December 31, 2010
Explicating an evidence-based, theoretically informed, mobile technology-based system to improve outcomes for people in recovery for alcohol dependenceDavid H Gustafson, Bret R Shaw, Andrew Isham, et al.Respiratory Medicine|December 5, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspectiveMaurice Driessen, Dhvani Shah, Nancy Risebrough, et al.Cost Effectiveness and Resource Allocation : C/E|May 19, 2018
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspectiveDhvani Shah, Maurice Driessen, Nancy Risebrough, et al.Pharmacoeconomics - Open|August 25, 2022
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067Timothy Baker, Helen Johnson, Srividya Kotapati, et al.Pageof 5